IMGO
Closed
Imago Biosciences Inc
36.01
0.00 (0.00%)
Last Update: 13 Jan 2023 17:30:00
Yesterday: 36.01
Day's Range: 36.01 - 36.01
Send
sign up or login to leave a comment!
When Written:
36.01
Imago Biosciences Inc is a clinical-stage biotechnology company that is focused on developing innovative treatments for cancer and other diseases. The company's lead product candidate, IMG-7289, is a small molecule inhibitor of lysine-specific demethylase 1 (LSD1), which is an enzyme that plays a key role in the regulation of gene expression. By inhibiting LSD1, IMG-7289 has the potential to restore normal gene expression in cancer cells, leading to the suppression of tumor growth.
Imago Biosciences was founded in 2013 and is based in San Francisco, California. The company has raised over $100 million in funding from investors such as Frazier Healthcare Partners, Omega Funds, and Amgen Ventures. In addition to IMG-7289, Imago Biosciences is also developing other small molecule inhibitors for the treatment of cancer and other diseases. The company's mission is to improve the lives of patients by developing novel therapies that address unmet medical needs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Imago Biosciences was founded in 2013 and is based in San Francisco, California. The company has raised over $100 million in funding from investors such as Frazier Healthcare Partners, Omega Funds, and Amgen Ventures. In addition to IMG-7289, Imago Biosciences is also developing other small molecule inhibitors for the treatment of cancer and other diseases. The company's mission is to improve the lives of patients by developing novel therapies that address unmet medical needs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








